Critical advancements in IgAN treatments and understanding of risk factors.
Breakthroughs, management options, and the impact of kidney disease on reproductive health
Biogen's Phase 2 Success, Oxford Classification for Pediatric Outcomes, and Nefecon's Long-term Management Potential.
Significant funding milestones for IgA nephropathy gene therapy and, innovative predictive tools for paediatric care
